Monday, July 06, 2020 8:04:44 AM
In a report released today, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Acasti Pharma (ACST), with a price target of $2.00. The company’s shares closed last Thursday at $0.53, close to its 52-week low of $0.25.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 22.1% and a 52.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Acasti Pharma is a Moderate Buy with an average price target of $3.34, a 554.9% upside from current levels. In a report issued on June 30, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target...:party:
Ones entry is only as good as the exit strategy...
Recent ACST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 01:00:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 12:30:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 01:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:08:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:08:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 12:30:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 12:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 08:30:18 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/16/2023 08:31:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:30:09 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/06/2023 08:30:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2023 11:46:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 12:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2023 07:54:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/25/2023 09:01:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/25/2023 08:21:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/25/2023 08:15:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 11:31:17 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 11:15:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 09:30:28 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM